Comparison · NCT00777179-5ce8945f
Vandetanib vs Placebo: Progression-free Survival (PFS) Rate at 3 Months
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib vs Placebo: Progression-free Survival (PFS) Rate at 3 Months. Trial comparisons, record NCT00777179-5ce8945f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00777179-5ce8945f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.444 | 0.328 | 0.567 | wilson | |
| Risk in group 2 | 0.316 | 0.191 | 0.475 | wilson | |
| Risk difference, group 1 minus group 2 | 0.129 | -0.068 | 0.304 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.41 | 0.817 | 2.42 | log | |
| Odds ratio, group 1 over group 2 | 1.73 | 0.744 | 4.04 | log | |
| Number needed to treat, for one more participant with the outcome on Vandetanib than on Placebo | 7.77 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib | Vandetanib 300 mg, orally, once daily | 28 | 63 | OG000 |
| Group 2 | Placebo | Matching Placebo | 12 | 38 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Progression-free Survival (PFS) Rate at 3 Months
- Description
- Progression-free survival (PFS) rate at 3 months is defined as the number of patients without evidence of progression or death after 3 months from randomisation among the PFS-evaluable patients.
- Time frame
- 12 weeks
- Population
- The reported number of participants analyzed (Vandetanib: 63, Placebo: 38) are for PFS evaluable patient set.
Source ClinicalTrials.gov
Trial
- Title
- Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
- NCT number
- NCT00777179
- Phases
- PHASE2
- Conditions
- NSCLC
- Interventions
- Vandetanib, Placebo
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2011-07-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00777179?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00777179-5ce8945f